Annelotte C M van Bommel1,2, Pauline E R Spronk1,2, Marie-Jeanne T F D Vrancken Peeters3, Agnes Jager4, Marc Lobbes5, John H Maduro6, Marc A M Mureau7, Kay Schreuder8, Carolien H Smorenburg9, Janneke Verloop8, Pieter J Westenend10, Michel W J M Wouters2,11, Sabine Siesling12,13, Vivianne C G Tjan-Heijnen14, Thijs van Dalen15. 1. Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. 2. Dutch Institute for Clinical Auditing, Leiden, The Netherlands. 3. Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 4. Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands. 5. Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands. 6. Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. 7. Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands. 8. Department of Research, Comprehensive Cancer Organisation the Netherlands (IKNL), Utrecht, The Netherlands. 9. Department of Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 10. Department of Pathology, Laboratory for pathology Dordrecht e.o., Dordrecht, The Netherlands. 11. Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 12. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 13. Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. 14. Department of Medical Oncology, Maastricht University Medical Centre, GROW-School for Oncology and Developmental Biology, Maastricht, The Netherlands. 15. Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND: In 2011, the NABON Breast Cancer Audit (NBCA) was instituted as a nation-wide audit to address quality of breast cancer care and guideline adherence in the Netherlands. The development of the NBCA and the results of 4 years of auditing are described. METHODS: Clinical and pathological characteristics of patients diagnosed with invasive breast cancer or in situ carcinoma (DCIS) and information regarding diagnosis and treatment are collected in all hospitals (n = 92) in the Netherlands. Thirty-two quality indicators measuring care structure, processes and outcomes were evaluated over time and compared between hospitals. RESULTS: The NBCA contains data of 56,927 patients (7,649 DCIS and 49,073 invasive cancers). Patients being discussed in pre- and post-operative multidisciplinary team meetings improved (2011: 83% and 91%; 2014: 98% and 99%, respectively) over the years. Tumour margin positivity rates after breast-conserving surgery for invasive cancer requiring re-operation were consistently low (∼5%). Other indicators, for example, the use of an MRI-scan prior to surgery or immediate breast reconstruction following mastectomy showed considerable hospital variation. CONCLUSIONS: Results shown an overall high quality of breast cancer care in all hospitals in the Netherlands. For most quality indicators improvement was seen over time, while some indicators showed yet unexplained variation. J. Surg. Oncol. 2017;115:243-249.
BACKGROUND: In 2011, the NABON Breast Cancer Audit (NBCA) was instituted as a nation-wide audit to address quality of breast cancer care and guideline adherence in the Netherlands. The development of the NBCA and the results of 4 years of auditing are described. METHODS: Clinical and pathological characteristics of patients diagnosed with invasive breast cancer or in situ carcinoma (DCIS) and information regarding diagnosis and treatment are collected in all hospitals (n = 92) in the Netherlands. Thirty-two quality indicators measuring care structure, processes and outcomes were evaluated over time and compared between hospitals. RESULTS: The NBCA contains data of 56,927 patients (7,649 DCIS and 49,073 invasive cancers). Patients being discussed in pre- and post-operative multidisciplinary team meetings improved (2011: 83% and 91%; 2014: 98% and 99%, respectively) over the years. Tumour margin positivity rates after breast-conserving surgery for invasive cancer requiring re-operation were consistently low (∼5%). Other indicators, for example, the use of an MRI-scan prior to surgery or immediate breast reconstruction following mastectomy showed considerable hospital variation. CONCLUSIONS: Results shown an overall high quality of breast cancer care in all hospitals in the Netherlands. For most quality indicators improvement was seen over time, while some indicators showed yet unexplained variation. J. Surg. Oncol. 2017;115:243-249.
Authors: Rawa Kamaran Ismail; Jesper van Breeschoten; Silvia van der Flier; Caspar van Loosen; Anna Maria Gerdina Pasmooij; Maaike van Dartel; Alfons van den Eertwegh; Anthonius de Boer; Michel Wouters; Doranne Hilarius Journal: J Med Internet Res Date: 2022-06-23 Impact factor: 7.076
Authors: Naomi Beck; Fieke Hoeijmakers; Erwin M Wiegman; Hans J M Smit; Franz M Schramel; Willem H Steup; Ad F T M Verhagen; Wilhelmina H Schreurs; Michel W J M Wouters Journal: J Thorac Dis Date: 2018-10 Impact factor: 2.895
Authors: Marc B I Lobbes; Ingeborg J H Vriens; Annelotte C M van Bommel; Grard A P Nieuwenhuijzen; Marjolein L Smidt; Liesbeth J Boersma; Thijs van Dalen; Carolien Smorenburg; Henk Struikmans; Sabine Siesling; Adri C Voogd; Vivianne C G Tjan-Heijnen Journal: Breast Cancer Res Treat Date: 2017-01-28 Impact factor: 4.872
Authors: Mathijs P Hendriks; Xander A A M Verbeek; Jeannette G van Manen; Sannah E van der Heijden; Shirley H L Go; Gea A Gooiker; Thijs van Vegchel; Sabine Siesling; Agnes Jager Journal: Breast Cancer Res Treat Date: 2020-07-06 Impact factor: 4.872
Authors: E Heeg; M B Jensen; M A M Mureau; B Ejlertsen; R A E M Tollenaar; P M Christiansen; M T F D Vrancken Peeters Journal: Breast Cancer Res Treat Date: 2020-06-10 Impact factor: 4.872
Authors: Laurien S Kuhrij; Michel Wjm Wouters; Renske M van den Berg-Vos; Frank-Erik de Leeuw; Paul J Nederkoorn Journal: Eur Stroke J Date: 2018-07-11
Authors: Janine M Simons; Thiemo J A van Nijnatten; Carmen C van der Pol; Ernest J T Luiten; Linetta B Koppert; Marjolein L Smidt Journal: Ann Surg Date: 2019-03 Impact factor: 12.969
Authors: Laura Biganzoli; Fatima Cardoso; Marc Beishon; David Cameron; Luigi Cataliotti; Charlotte E Coles; Roberto C Delgado Bolton; Maria Die Trill; Sema Erdem; Maria Fjell; Romain Geiss; Mathijs Goossens; Christiane Kuhl; Lorenza Marotti; Peter Naredi; Simon Oberst; Jean Palussière; Antonio Ponti; Marco Rosselli Del Turco; Isabel T Rubio; Anna Sapino; Elzbieta Senkus-Konefka; Marko Skelin; Berta Sousa; Tiina Saarto; Alberto Costa; Philip Poortmans Journal: Breast Date: 2020-02-26 Impact factor: 4.380